Clinical laboratory diagnostics of antibodies to SARS-CoV-2: from a QR code to the reality
- Authors: Shansky Y.D.1, Gospodarik A.V.1, Komarova A.V.1,2, Esiev S.S.1, Ulakhanova L.A.1, Serkina A.S.1, Plotnikova L.V.1,2, Bespyatykh J.A.1,2,3
-
Affiliations:
- Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency
- Mendeleev University of Chemical Technology of Russia
- N.A. Semashko National Research Institute of Public Health
- Issue: Vol 14, No 1 (2023)
- Pages: 12-20
- Section: Original Study Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/142797
- DOI: https://doi.org/10.17816/clinpract163553
- ID: 142797
Cite item
Full Text
Abstract
Background: The immune response to SARS-CoV-2 includes the production of specific immunoglobulins to protein antigens of SARS-CoV-2. Depending on the type and level of immunoglobulins, it is possible to assess the stage of the disease and evaluate the effectiveness of vaccination. The main approach to the determination of immunoglobulins to SARS-CoV-2 in human biological fluids is enzyme-linked sorbent immunoassay. Its data, in particular, are used to issue an electronic COVID-19 certificate with a QR code. However, the qualitative and quantitative composition of immunoglobulins for a QR code is not officially regulated.
Aim: measuring the immunoglobulins’ level in the human blood serum with different types of immunity to the new coronavirus infection (COVID-19) to select the most informative indicators of protective immunity.
Methods: The study included 76 blood serum samples from male and female volunteers (age, 18 to 50 y.o.) in compliance with the ethical standards. The detection of IgA, IgM, IgG (total to different regions of SARS-CoV-2, S-protein IgG and RBD-fragment IgG), IgG avidity, and the level of the SARS-CoV-2 N-antigen was performed by enzyme-linked immunosorbent assay (ELISA) using commercially available reagent kits.
Results: The indicators of the level of antibodies (both "protective" IgG and IgA of the initial phase of infection) are most pronounced in persons who have been vaccinated and have had COVID-19, and least pronounced in unvaccinated people. For recovered unvaccinated individuals, the level of total “protective” antibodies and IgG to the S-protein, including the RBD fragment, is the lowest; the avidity of IgG is lower than that in the other groups, too. The IgG avidity in vaccinated patients is higher than that in recovered ones. It should be noted that there were no differences in the level of both total IgG to SARS-CoV-2, to the S-protein and to the RBD-fragment of the S-protein for recovered and vaccinated individuals.
Conclusion: The analysis of COVID-19 immunoglobulins indicates a different profile of the humoral immune response following vaccination and previous infection with COVID-19. To quickly assess the immune response to previous and current COVID-19 infection, as well as to detect the post-vaccination immunity, it is advisable to use the total level of IgG to SARS-CoV-2. For deeper assessment of protective immunity and production of protective antibodies, it is better to evaluate the quantitative content of IgG to the S protein and its RBD fragment. The equal level of IgA in the experimental groups indicates an ongoing interaction with SARS CoV-2 in the population. Thus, the electronic COVID-19 certificate is of little use when it is formed by only one of the indicators without taking into account the rest.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Yaroslav D. Shansky
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency
Author for correspondence.
Email: yar.shansky@rcpcm.org
ORCID iD: 0000-0003-4672-2474
SPIN-code: 7640-5940
PhD, Research Associate
Russian Federation, 1A Malaya Pirogovskaya street, 119435 MoscowAlina V. Gospodarik
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency
Email: alina.gospodaryk@rcpcm.org
PhD, Research Associate
Russian Federation, 1A Malaya Pirogovskaya street, 119435 MoscowAnastacia V. Komarova
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency; Mendeleev University of Chemical Technology of Russia
Email: komaanasta@yandex.ru
SPIN-code: 3694-1084
Junior Research Associate
Russian Federation, 1A Malaya Pirogovskaya street, 119435 Moscow; MoscowSulejman S. Esiev
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency
Email: kap20081@gmail.com
SPIN-code: 9593-2893
Lab technician
Russian Federation, 1A Malaya Pirogovskaya street, 119435 MoscowLudmila A. Ulakhanova
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency
Email: ulahanova@mail.ru
SPIN-code: 6284-8699
Junior Research Associate
Russian Federation, 1A Malaya Pirogovskaya street, 119435 MoscowAnna S. Serkina
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency
Email: anny.serkina@yandex.ru
lab technician
Russian Federation, 1A Malaya Pirogovskaya street, 119435 MoscowLyudmila V. Plotnikova
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency; Mendeleev University of Chemical Technology of Russia
Email: ntmdfs@gmail.com
студент-магистрант 2 года
Russian Federation, 1A Malaya Pirogovskaya street, 119435 Moscow; MoscowJulia A. Bespyatykh
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency; Mendeleev University of Chemical Technology of Russia; N.A. Semashko National Research Institute of Public Health
Email: JuliaBes@rcpcm.org
ORCID iD: 0000-0002-4408-503X
SPIN-code: 6003-9246
PhD, Assistant Professor
Russian Federation, 1A Malaya Pirogovskaya street, 119435 Moscow; Moscow; MoscowReferences
- Маянский Н.А., Бржозовская Е.А., Стоянова С.С., и др. Динамика концентрации антител к SARS-CoV-2 в течение 12 месяцев после перенесенной инфекции COVID-19 // Вестник Российского государственного медицинского университета. 2022. № 1. С. 11–13. [Mayansky NA, Brzhozovskaya EA, Stoyanova SS, et al. Dynamic changes in the concentration of anti-SARS-CoV-2 antibodies within 12 months after recovery from COVID-19. Bulletin of Russian state medical university. 2022;(1):11–13. (In Russ).] doi: 10.24075/vrgmu.2022.007
- Kim Y., Lee J.H., Ko G.Y., et al. Quantitative SARS-CoV-2 spike antibody response in COVID-19 patients using three fully automated immunoassays and a surrogate virus neutralization test. Diagnostics. 2021;11:1496. doi: 10.3390/diagnostics11081496
- Yuan H, Chen P, Wan C, et al. Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19. TrAC Trends Anal Chem. 2022;157: 116814. doi: 10.1016/J.TRAC.2022.116814
- Drain PK, Ampajwala M, Chappel C, et al. A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care: A clinical performance study. Infect Dis Ther. 2021;10:753–761. doi: 10.1007/S40121-021-00413-X/FIGURES/2
- Приказ Министерства здравоохранения Российской Федерации от 4 февраля 2022 г. N 58н «О внесении изменений в приложения N 3 и N 4 к приказу Министерства здравоохранения Российской Федерации от 12.11.2021 N 1053н “Об утверждении формы медицинской документации “Справка о проведенных профилактических прививках против новой коронавирусной инфекции (COVID-19) или наличии медицинских противопоказаний к вакцинации” и порядка ее выдачи, формы медицинской документации “Медицинский сертификат о профилактических прививках против новой коронавирусной инфекции (COVID-19) или медицинских противопоказаниях к вакцинации и (или) перенесенном заболевании, вызванном новой коронавирусной инфекцией (COVID-19)” и порядка ее ведения, а также формы “Сертификат о профилактических прививках против новой коронавирусной инфекции (Covid-19) или медицинских противопоказаниях к вакцинации и (или) перенесенном заболевании, вызванном новой коронавирусной инфекцией (COVID-19)”». [The order of the Ministry of Health of the Russian Federation “O vnesenii izmeneniy v prilozheniya N 3 i N 4 k prikazu Ministerstva zdravookhraneniya Rossiyskoy Federatsii ot 12.11.2021 N 1053n “Ob utverzhdenii formy meditsinskoy dokumentatsii “Spravka o provedennykh profilakticheskikh privivkakh protiv novoy koronavirusnoy infektsii (COVID-19) ili nalichii meditsinskikh protivopokazaniy k vaktsinatsii” i poryadka yeye vydachi, formy meditsinskoy dokumentatsii “Meditsinskiy sertifikat o profilakticheskikh privivkakh protiv novoy koronavirusnoy infektsii (COVID-19) ili meditsinskikh protivopokazaniyakh k vaktsinatsii i (ili) perenesennom zabolevanii, vyzvannom novoy koronavirusnoy infektsiyey (COVID-19)” i poryadka yeye vedeniya, a takzhe formy “Sertifikat o profilakticheskikh privivkakh protiv novoy koronavirusnoy infektsii (COVID-19) ili meditsinskikh protivopokazaniyakh k vaktsinatsii i (ili) perenesennom zabolevanii, vyzvannom novoy koronavirusnoy infektsiyey (COVID-19)”». (In Russ).] Режим доступа: http://publication.pravo.gov.ru/Document/View/0001202202080016. Дата обращения: 18.01.2023.
- Баклаушев В.П., Юсубалиева Г.М., Бычинин М.В., и др. Рациональная стратегия поддержания противовирусного иммунитета к новым вариантам SARS-CoV-2 // Клиническая практика. 2022. Т. 13, № 3. С. 43–55. [Baklaushev VP, Yusubalieva GM, Bychinin MV, et al. A rational strategy for the maintenance of antiviral immunity to new SARS-CoV-2 strains. Journal of Clinical Practice. 2022;13(3):43–55. (In Russ).] doi: 10.17816/clinpract111120
- Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17 (14.12.2022)» (утв. заместителем Министра здравоохранения Российской Федерации А.Н. Плутницким). [Vremennyye metodicheskiye rekomendatsii «Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19). V. 17 (14.12.2022)» (utv. zamestitelem Ministra zdravookhraneniya Rossiiskoi Federatsii A.N. Plutnitskim). (In Russ).] Режим доступа: https://normativ.kontur.ru/document?moduleId=1&documentId=438135. Дата обращения: 18.01.2023.
- Zhou Y, Chen Y, Liu W, et al. Development of a rapid and sensitive quantum dot nanobead-based double-antigen sandwich lateral flow immunoassay and its clinical performance for the detection of SARS-CoV-2 total antibodies. Sensors Actuators B Chem. 2021;343:130139. doi: 10.1016/J.SNB.2021.130139
- Hajazadeh F, Khanizadeh S, Khodadadi H, et al. SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study). Microb Pathog. 2022;168:105595. doi: 10.1016/J.MICPATH.2022.105595
- Heggestad JT, Kinnamon DS, Olson LB, et al. Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test. Sci Adv. 2021;7:4901–4926. doi: 10.1126/SCIADV.ABG4901
- Gan HH, Zinno J, Piano F, Gunsalus KC. Omicron spike protein has a positive electrostatic surface that promotes ACE2 recognition and antibody escape. Front Virol. 2022;2:43. doi: 10.3389/FVIRO.2022.894531
- Zhuo R, Charlton C, Plitt S, et al. Comparison of SARS-CoV-2 spike antibody quantitative titer reporting using the World Health Organization International Standard Units by four commercial assays. Journal of Clinical Virology. 2022;(156):105292. doi: 10.1016/j.jcv.2022.105292
- Liao B, Chen Z, Zheng P, et al. Detection of anti-SARS-CoV-2-S2 IgG is more sensitive than anti-RBD IgG in identifying asymptomatic COVID-19 patients. Front Immunol. 2021;12:724763. doi: 10.3389/fimmu.2021.724763
- Xiao K, Yang H, Liu B, et al. Antibodies can last for more than 1 year after SARS-CoV-2 infection: A follow-up study from survivors of COVID-19. Front Med. 2021;8:967. doi: 10.3389/fmed.2021.684864
- Генералова Л.В., Григорьев И.В., Васина Д.В., и др. Свойства антител к RBD у переболевших COVID-19 и вакцинированных препаратом «Спутник V» // Вестник Российского государственного медицинского университета. 2022. № 1. С. 15–22. [Generalova LV, Grigor’yev IV, Vasina DV, et al. Properties of RBD specific IgG from COVID-19 patients and Sputnik V vaccinated individuals. Bulletin of Russian state medical university. 2022;(1):15–22. (In Russ).] doi: 10.24075/vrgmu.2022.005